INDUSTRY UPDATE

Healthcare Monday, January 11, 2016



Raweenuch Piyakriengkai Fundamental Investment Analyst on Securities (66-2) 949-1002 raweenuch.piyakriengkai@scb.co.th

Preview 4Q15: Resilience supports further rally

The Thai healthcare sector index surged 30% in 2015 vs. a 14% dip for the SET Index and we expect the rally to continue: this sector is a safe haven for investors, with solid earnings amidst a cautious economic view for 2016. Our top pick is BDMS, backed by strong earnings growth and growth opportunities in the AEC.

4Q15F preview. Of its sector, we expect BH to report the strongest earnings growth both YoY and QoQ at Bt873mn, up 30% YoY and 5% QoQ, backed by improvement from its low base last year and an exceptionally weak 3Q15 on concerns of MERS and the bomb at Erawan Shrine. BDMS' core earnings are expected to be flat YoY, with growth at existing hospitals offset by losses from newly-opened hospitals, with an 11% decline QoQ on seasonality. We expect BCH's core earnings to drop YoY due to losses at new hospitals (open in mid-2015) with a seasonal fall QoQ.

Accelerating earnings growth in 2016. The healthcare sector is poised to deliver 16% YoY core earnings growth this year, accelerating from 10% YoY in 2015. **BCH**: We expect it to report the strongest core earnings growth at 25% YoY in 2016 after three years of contractions, largely from a steady easing in losses at World Medical Center (WMC), its high-end hospital. **BDMS**: We expect earnings to jump 17% YoY in 2016 (from the limp 2% YoY in 2015) backed by growing revenue and wider EBITDA margin supported by strong operations at its 28 existing hospitals, operational ramp-up at 14 newly-opened hospitals (less than two years in operation) and less drag from new investment - it plans to open only one new hospital in 2016. **BH**: After the outstanding 31% YoY growth in 2015 due to improving operations (and off the low base from the political tension), we expect core earnings growth to return to normal at 13% YoY.

AEC is a growth opportunity for BDMS. BDMS has solid growth opportunities from the startup of the ASEAN Economic Community (AEC) with rising demand for more advanced healthcare in the region, particularly from CLMV countries. It already operates two hospitals in Cambodia and has hospitals in Thailand near borders: Bangkok Hospital Udon (in the northeast, adjoining Laos) and Bangkok Hospital Chiang Mai (in the north, near Myanmar). In 9M15, revenue from patients from Myanmar was only 1.9% of BDMS' total revenue vs. 9% for BH – indicating ample room to grow.

BDMS and BH: TPs increase as we roll over to end-2016. We roll over TPs for BDMS and BH to end-2016 from mid-2016. This raises BDMS' TP to Bt25/share (from Bt23/share) and BH's TP to Bt190/share (from Bt175/share). We already moved BCH's TP to end-2016 (Bt10/share).

Maintain positive view for the sector. BDMS is top pick. The Thai healthcare sector index surged 30% in 2015 (+50% for BH, +30% for BDMS and +15% for BCH) vs. a 14% dip for the SET Index. We expect this resilient sector to continue to outperform, however, as it provides a safe haven with solid growth – healthcare is a necessity - despite the cautious view towards the economy in 2016. BDMS is our top pick. Its valuation is not cheap, trading at 2.3x 2016PE-to-earnings growth, higher than the 2.1x regional average, but we see the premium valuation as deserved given its healthy earnings and bright prospects over the long haul, with a large and widespread network that will serve healthcare demand in Thailand and in its neighbors.

Valuation Summary

			.,																			
	Rating Price Target ETR			P/E (x)			EPS growth (%)			P/BV (x)			ROE (%)			Div. Yield (%)			EV/EBITDA (x)			
		(Bt/Sh)	(Bt/Sh)	(%)	14A	15F	16F	14A	15F	16F	14A	15F	16F	14A	15F	16F	14A	15F	16F	14A	15F	16F
BDMS	Buy	21.50	25.0	17.6	46.9	45.4	38.9	16	3	17	6.8	6.4	5.9	16	15	16	1.1	1.1	1.3	28.4	26.3	23.0
BCH	Buy	9.40	10.0	7.6	44.9	50.5	40.6	(11)	(11)	24	5.0	4.9	4.6	11	10	12	0.7	1.0	1.2	19.0	19.8	17.1
BH	Sell	217.00	190.0	(11.2)	58.9	45.1	39.8	9	31	13	16.7	14.6	12.7	26	29	29	0.9	1.1	1.3	34.1	27.3	24.9
Average					50.2	47.0	39.8	5	8	18	9.5	8.6	7.7	18	18	19	0.9	1.1	1.3	27.1	24.5	21.7

Source: SCBS Investment Research

Tel. (662) 949-1000 Fax: (662) 949-1030 www.scbs.com The information in this report has been obtained from sources believed to be reliable. However, its accuracy or completeness is not guaranteed. Any opinions expressed herein reflect our judgment at this date and are subject to change without notice. This report is for information only. It is not to be construed as an offer, or solicitation of an offer to sell or buy any securities. We accept no liability for any loss arising from the use of this document. We or our associates may have an interest in the companies mentioned therein.

Core profit												YoY gr	owth
(Bt mn)	4Q14	1Q15	2Q15	3Q15	4Q15F	% YoY %	% QoQ	Comment	2014	2015F	2016F	2015F	2016F
BCH	144	95	98	144	127	(11.8)	. ,	YoY core earnings drop due to losses from new hospitals (opening in mid-2015); QoQ core earnings drop is seasonal.		464	577	(11.2)	24.5
BDMS	1,693	2,289	1,491	1,879	1,677	(1.0)		EBITDA margin is expected to be flat as the improvement at older hospitals is unable to fully offset losses from the newer ones (14 newly-opened hospitals).	7,109	7,336	8,564	3.2	16.7
BH	674	962	836	831	873	29.6		Better QoQ core earnings are due to an exceptionally weak 3Q15 from concerns on MERS and bomb at Erawan Shrine.	2,684	3,503	3,969	30.5	13.3
Sector	2,511	3,346	2,426	2,854	2,678	6.6	(6.2)		10,314	11,303	13,111	9.6	16.0

Source: SCBS Investment Research

Figure 2: Regional peer valuation

			PE (x)		EPS Growth (%)			PBV (x)			Div. Yield (%)			ROE (%)			EV/EBITDA (x)		
Ticker	Country	15F	16F	17F	15F	16F	17F	15F	16F	17F	15F	16F	17F	15F	16F	17F	15F	16F `	17 F
BCH TB Equity*	Thailand	50.5	40.6	33.1	-11.1	24.5	22.5	4.9	4.6	4.3	1.0	1.2	1.5	9.8	11.6	13.3	19.8	17.1	14.6
BDMS TB Equity	 Thailand 	45.6	39.1	33.0	3.2	16.7	18.5	6.5	6.0	5.5	1.1	1.3	1.5	14.6	15.9	17.3	26.4	23.1	20.2
BH TB Equity*	Thailand	45.1	39.8	35.3	30.5	13.3	12.8	12.2	10.7	9.2	1.1	1.3	1.4	29.0	28.6	28.1	27.3	24.9	22.1
CHG TB Equity	Thailand	54.0	42.9	35.5	13.6	26.0	20.6	9.9	9.0	8.2	0.9	1.1	1.4	18.6	21.2	23.0	35.3	28.4	23.6
KPJ MK Equity	Malaysia	30.5	27.9	25.0	1.0	9.2	11.6	3.2	3.0	2.9	1.6	1.8	1.9	11.1	11.3	11.9	15.6	14.0	12.6
IHH MK Equity	Malaysia	56.3	46.0	37.7	24.5	22.6	22.0	2.6	2.5	2.4	0.5	0.6	0.7	4.5	5.6	6.4	26.7	23.0	20.1
RFMD SP Equity	Singapore	33.8	29.9	26.0	1.7	13.0	15.1	4.0	3.7	3.3	1.3	1.4	1.6	12.3	12.9	13.7	24.8	21.2	18.1
APHS IN Equity	India	50.5	41.5	32.3	10.7	21.7	28.6	5.7	5.2	4.6	0.5	0.5	0.7	11.7	13.5	16.4	25.1	21.1	17.6
RHC AU Equity	Australia	28.7	25.1	22.7	20.1	14.5	10.5	6.7	6.0	5.3	1.8	2.1	2.3	23.4	24.0	23.6	13.1	11.7	10.9
RYM NZ Equity	New Zealand	28.0	24.2	20.9	0.2	15.7	16.0	3.5	3.1	2.6	1.8	2.1	2.4	14.3	14.4	13.7	19.2	18.2	15.1
	Average	42.3	35.7	30.1	9.4	17.7	17.8	5.9	5.4	4.8	1.2	1.3	1.5	14.9	15.9	16.7	23.3	20.3	17.5
Sourco: Bloomb	org																		

Source: Bloomberg *SCBS estimates



Healthcare

Disclaimer

SCB SECURITIES COMPANY LIMITED ("SCBS") ACTS AS MARKET MAKER AND ISSUER OF DERIVATIVE WARRANTS on the ordinary shares of AAV, ADVANC, AMATA, ANAN, AOT, AP, BANPU, BBL, BCP, BDMS, BH, BJCHI, BLAND, CENTEL, CKP, DTAC, EARTH, GFPT, GLOBAL, GUNKUL, HANA, ICHI, INTUCH, IRPC, IVL, JAS, KBANK, KCE, KTB, LPN, MAJOR, MINT, PS, PSL, PTT, PTTEP, PTTGC, QH, S, SAWAD, SCC, SGP, SPALI, STPI, SVI, THAI, TMB, TOP, TRUE, TTA, TTCL, UNIO.

Before making an investment decision over a derivative warrant, an investor should carefully read the prospectus for the details of the said derivative warrants. Any opinion, news, research, analyse, price, statement, forecast, projection and/or other information contained in this document (the "Information") is provided as general purpose information only, and shall not be construed as a recommendation to any person of an offer to buy or sell, or the solicitation of an offer to buy or sell, any securities. SCBS and/or its directors, officers, employees, and agents shall not be liable for any direct, indirect, incidental, special or consequential loss or damage, resulting from the use of, or reliance on, the Information, including without limitation, damages for loss of profits. The investor should use the Information in association with other information and opinion, including his/her own judgment in making investment decision. The Information is obtained from sources believed to be reliable, and SCBS cannot guarantee the accuracy, completeness and/or correctness of the Information.

SCBS reserves the right to modify the Information from time to time at its sole discretion without giving any notice. This document is delivered to intended recipient(s) only and is not permitted to reproduce, retransmit, disseminate, sell, distribute, republish, circulate or commercially exploit the Information in any manner without the prior written consent of SCBS.

CG Rating 2015 Companies with CG Rating

ADVANC, BAFS, BCP, BIGC, BTS, CK, CPN, DRT, DTAC, DTC, EASTW, EGCO, GRAMMY, HANA, HMPRO, INTUCH, IRPC, IVL, KBANK, KCE, KKP, KTB, LHBANK, LPN, MCOT, MINT, MONO, NKI, PHOL, PPS, PS, PSL, PTT, PTTEP, PTTGC, QTC, RATCH, ROBINS, SAMART, SAMTEL, SAT, SC, SCB, SCC, SE-ED, SIM, SNC, SPALI, THCOM, TISCO, TKT, TMB, TOP, VGI, WACOA

AAV, ACAP, AGE, AHC, AKP, AMATA, ANAN, AOT, APCS, ARIP, ASIMAR, ASK, ASP, BANPU, BAY, BBL, BDMS, BECL, BKI, BLA, BMCL, BOL, BROOK, BWG, CENTEL, CFRESH, CHO, CIMBT, CM, CNT, Adv, Adv, Adv, Adv, And, An, Anata, Anana, Adt, Apes, Antr, Astivian, Ass, Bonned, Bat, Bal, Buns, Bell, Bat, Bell, Bat, Bell, Buns, WINNER, YUASA, ZMICO

444

25, AEC, AEONTS, AF, AH, AIRA, AIT, AJ, AKR, AMANAH, AMARIN, AP, APCO, AQUA, AS, ASIA, AUCT, AYUD, BA, BEAUTY, BEC, BFIT, BH, BIG, BJC, BJCHI, BKD, BTNC, CBG, CGD, CHG, CHOW, VPO, WHA, WIN, XO

Corporate Governance Report

The disclosure of the survey result of the Thai Institute of Directors Association ("IOD") regarding corporate governance is made pursuant to the policy of the Office of the Securities and Exchange Commission. The survey of the IOD is based on the information of a company listed on the Stock Exchange of Thailand and the Market for Alternative Investment disclosed to the public and able to be accessed by a general public investor. The result, therefore, is from the perspective of a third party. It is not an evaluation of operation and is not base on inside information. The survey result is as of the date appearing in the Corporate Governance Report of Thai Listed Companies. As a result, the survey result may be changed after that date. SCB Securities Company Limited does not conform nor certify the accuracy of such survey result.

Anti-corruption Progress Indicator 2015 Level 5: Extended (ขยายผลสู่ผู้ที่เกี่ยวข้อง)

BCP, CPN, GYT, PE, PM, PPP, PT, PTT, PTTGC SAT, SCC, THANI, TOP

Level 4: Certified (ได้รับการรับรอง)

ASP, BAFS, BANPU, BAY, BBL, BKI, BLA, CIMBT, CNS, CSL, DCC, DRT, DTC, EASTW, ECL, EGCO, ERW, FSS, GCAP, HANA, HTC, INTUCH, IRPC, IVL, KBANK, KCE, KGI, KKP, KTB, LANNA, LHBANK, MTI, NKI, PSL, PTG, PTTEP, SABINA, SCB, SNC, SNP, SSF, SSSC, TCAP, THCOM, TISCO, TMB, TMD, TNITY, TOG

Level 3B: Established by Commitment and Policy (มีมาตรการป้องกัน ตามคำมั่นและนโยบาย) AAV, AHC, AIT, AKR, ARROW, ASK, BA, BDMS, BEC, BECL, BJCHI, BUI, CGH, CHG, CHOW, CIG, CITY, CK, CKP, COLOR, CWT, EARTH, EASON, EPG, F&D, FANCY, FIRE, FMT, FORTH, GENCO, GL, GOLD, GPSC, GRAMMY, HYDRO, IRCP, IT, JCT, KCM, KWC, LH, LIT, LOXLEY, MACO, MANRIN, MATI, MODERN, MSC, NOBLE, NOK, NPK, NUSA, OISHI, OTO, PAF, PAP, PATO, PF, PIW, PLANB, PLE, POLAR, PRG, PTL, Q-CON, QTC, RCI, S11, SALEE, SAM, SAMART, SAMTEL, SAPPE, SC, SCP, SFP, SIM, SLP, SMT, SPA, SPORT, SSC, SST, STEC, STPI, SUC, SUTHA, T, TAE, TBSP, TCC, TFD, TGCI, TGPRO, THANA, THIP, TIW, TK, TMW, TNDT, TOPP, TPC, TPCH, TPIPL, TSR, TT, TYCN, UAC, UBIS, UEC, UMI, UP, UPF, UT, UV, VPO, WAVE, WINNER, YUASA

Level 3A: Established by declaration of intent (มีมาตรการป้องกัน ตามคำประกาศเจตนารมณ์) ABC, ACAP, ADVANC, AGE, AH, AMANAH, ANAN, AP, APCS, APURE, AS, ASIA, ASIAN, ASIMAR, BIGC, BROOK, BTS, BWG, CEN, CENTEL, CFRESH, CHARAN, CHO, CHOTI, CM, CNT, COL, CPF, CPI,

Level 2: Declared (ประกาศเจตนารมณ์)

25, ABICO, AF, AKP, AMARIN, AMARIA, AOT, APCO, AYUD, BEAUTY, BFIT, BH, BKD, BLAND, BTNC, CCP, CI, CSR, CSS, EFORL, EPCO, FE, FNS, FVC, GEL, GLOBAL, HEMRAJ, IEC, IFS, INET, JUTHA, KASET, KCAR, KKC, KSL, L&E, LALIN, LTX, M, MALEE, MBK, MBKET, MEGA, MK, MPG, MTLS, NCH, NCL, NPP, OCC, OCEAN, PB, PCA, PRINC, QH, ROCK, RPC, S & J, SGP, SIAM, SIS, SKR, SMG, SMIT, SORKON, SUSCO, TAKUNI, TEAM, TF, TIC, TIP, TIPCO, TMC, TMI, TPP, TRT, TRU, TRUE, TSC, TSI, TTW, TVD, TVO, UKEM, UNIQ, UWC, VNG, WIIK, WIN, XO

Level 1: Committed (ขยายผลสู่ผู้ที่เกี่ยวข้อง) ACD, AEONTS, AFC, AIRA, AJ, ALUCON, AMC, AQUA, ARIP, AUCT, BAT-3K, BIG, BJC, BMCL, BOL, BRR, BSBM, CBG, CCET, CCN, CGD, CMR, CPH, CSC, CSP, CTW, DCON, DRACO, DSGT, DTCI, E, UPOIC, UTP, UVAN, VARO, VI, VIBHA, VIH, VTE, WG

Anti-corruption Progress Indicator

The disclosure of the Anti-Corruption Progress Indicators of a listed company on the Stock Exchange of Thailand, which is assessed by Thaipat Institute, is made in order to comply with the policy and sustainable development plan for the listed companies of the Office of the Securities and Exchange Commission. Thaipat Institute made this assessment based on the information received from the listed company, as stipulated in the form for the assessment of Anti-Corruption which refers to the Annual Registration Statement (Form 56-1), Annual Report (Form 56-2), or other relevant documents or reports of such listed company. The assessment result is therefore made from the perspective of Thaipat Institute that is a third party. It is not an assessment of operations and is not based on any inside information. Since this assessment is only the assessment result as of the date appearing in the assessment result, it may be changed after that date or when there is any change to the relevant information. Nevertheless, SCB Securities Company Limited does not confirm, verify, or certify the accuracy and completeness of the assessment result.

Reference

Level 5: Extended – Extension of the anti-corruption policy to business partners in the supply chain, and disclosure of any current investigations, prosecutions or closed cases Level 4: Certified – Audit engagement by audit committee or auditors approved by the office of SEC, and receiving certification or assurance by independent external assurance providers (CAC etc.)

Level 3: Established – Carrying out preventive measures, risk assessment, communication and training for all employees, including consistent monitoring and review processes Level 3A: Established by declaration of intent. Level 3B: Established by Commitment and Policy

Level 2: Declared – Public declaration statement to participate in Thailand's private sector Collective Action Coalition Against Corruption (CAC) or equivalent initiatives

Level 1: Committed - Organization's statement or board's resolution to work against corruption and to be in compliance with all relevant laws

